MEDNAX Inc (NYSE:MD) Director Michael Fernandez purchased 122,409 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were acquired at an average cost of $21.35 per share, with a total value of $2,613,432.15. Following the purchase, the director now directly owns 350,288 shares of the company’s stock, valued at approximately $7,478,648.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Michael Fernandez also recently made the following trade(s):
- On Thursday, August 8th, Michael Fernandez purchased 64,242 shares of MEDNAX stock. The shares were acquired at an average cost of $21.68 per share, with a total value of $1,392,766.56.
NYSE MD traded up $0.48 during mid-day trading on Tuesday, reaching $21.82. 1,170,295 shares of the stock were exchanged, compared to its average volume of 1,057,027. MEDNAX Inc has a one year low of $20.43 and a one year high of $48.77. The company has a 50 day moving average of $23.75. The stock has a market cap of $1.81 billion, a PE ratio of 6.22, a P/E/G ratio of 0.83 and a beta of 0.67. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.23 and a current ratio of 2.23.
Several equities analysts have recently issued reports on the stock. Citigroup set a $36.00 price target on shares of MEDNAX and gave the company a “buy” rating in a research note on Friday, May 3rd. UBS Group dropped their price target on shares of MEDNAX to $20.00 and set a “sell” rating for the company in a research note on Wednesday, July 24th. Mizuho dropped their price target on shares of MEDNAX from $26.00 to $24.00 and set a “neutral” rating for the company in a research note on Friday, August 2nd. BMO Capital Markets dropped their price target on shares of MEDNAX from $32.00 to $25.00 and set a “market perform” rating for the company in a research note on Monday, August 5th. Finally, Zacks Investment Research downgraded shares of MEDNAX from a “hold” rating to a “sell” rating and set a $26.00 price target for the company. in a research note on Wednesday, July 3rd. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the stock. MEDNAX presently has an average rating of “Hold” and a consensus price target of $32.80.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Tompkins Financial Corp grew its holdings in MEDNAX by 352.8% in the first quarter. Tompkins Financial Corp now owns 806 shares of the company’s stock worth $38,000 after purchasing an additional 628 shares during the period. Quadrant Capital Group LLC grew its holdings in MEDNAX by 538.6% in the first quarter. Quadrant Capital Group LLC now owns 1,009 shares of the company’s stock worth $26,000 after purchasing an additional 851 shares during the period. Bremer Bank National Association acquired a new stake in MEDNAX in the first quarter worth $30,000. Meeder Asset Management Inc. acquired a new stake in MEDNAX in the second quarter worth $36,000. Finally, Investors Research Corp acquired a new stake in MEDNAX in the first quarter worth $41,000. 89.93% of the stock is owned by institutional investors and hedge funds.
MEDNAX Company Profile
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.
See Also: Correction
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.